AstraZeneca PLC (AZN)vsFemasys Inc (FEMY)
AZN
AstraZeneca PLC
$187.37
+1.17%
HEALTHCARE · Cap: $287.11B
FEMY
Femasys Inc
$0.37
-2.06%
HEALTHCARE · Cap: $24.58M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 2561231% more annual revenue ($58.74B vs $2.29M). AZN leads profitability with a 17.4% profit margin vs 0.0%. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
FEMY
Avoid25
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+4.1%
Fair Value
$214.51
Current Price
$187.37
$27.14 discount
Margin of Safety
+62.3%
Fair Value
$1.34
Current Price
$0.37
$0.97 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Earnings expanding 53.9% YoY
Every $100 of equity generates 23 in profit
Strong operational efficiency at 21.6%
Generating 1.4B in free cash flow
Revenue surging 39.9% year-over-year
Areas to Watch
Expensive relative to growth rate
Moderate valuation
4.1% revenue growth
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
ROE of -455.8% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, EPS Growth, Return on Equity. Profitability is solid with margins at 17.4% and operating margin at 21.6%.
Bull Case : FEMY
The strongest argument for FEMY centers on Revenue Growth. Revenue growth of 39.9% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are PEG Ratio, P/E Ratio, Revenue Growth.
Bear Case : FEMY
The primary concerns for FEMY are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
AZN profiles as a value stock while FEMY is a hypergrowth play — different risk/reward profiles.
AZN carries more volatility with a beta of 0.28 — expect wider price swings.
FEMY is growing revenue faster at 39.9% — sustainability is the question.
AZN generates stronger free cash flow (1.4B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (64/100 vs 25/100), backed by strong 17.4% margins. FEMY offers better value entry with a 62.3% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Femasys Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Femasys Inc. is a pioneering medical technology company dedicated to revolutionizing women's healthcare through its advanced proprietary solutions for diagnosing and treating gynecological conditions. The company is noted for its innovative flagship products that provide non-surgical alternatives for prevalent issues such as uterine fibroids and contraception, firmly establishing itself as a leader in the dynamic women's health landscape. As the demand for minimally invasive treatments escalates, Femasys is well-positioned to leverage this trend, delivering enhanced patient outcomes and improving healthcare efficiency. With a strong commitment to addressing substantial unmet needs in women’s health, Femasys seeks to transform the standards of care within this essential sector.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?